Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Elicera Therapeutics

5.96

 

SEK

 

-5.55 %

Less than 1K followers

ELIC

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Compare
-5.55%
+34.23%
+152.54%
+256.89%
+229.28%
+513.17%
+45.37%
-
-3.87%

Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.

Read more
Market cap
289.27M SEK
Turnover
2.61M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
29.8
2025

Interim report Q2'25

14.11
2025

Interim report Q3'25

13.2
2026

Annual report '25

All
Research
Press releases
3rd party
ShowingAll content types
Press release5/28/2025, 8:20 AM

Redeye: Elicera Therapeutics Q1 - Positive pattern emerging in CARMA trial

Elicera Therapeutics
Press release5/28/2025, 6:45 AM

Elicera Therapeutics enters a Material Transfer Agreement with University Hospital Tübingen for testing of the company's oncolytic virus candidates, ELC-100 and ELC-201

Elicera Therapeutics
Press release5/23/2025, 8:04 AM

BioStock: Promising preliminary results for Elicera Therapeutics’ CAR T-cell stud

Elicera Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release5/22/2025, 6:36 AM

Elicera Therapeutics: Elicera reports: Active lymphoma eliminated in two out of three patients in the first cohort of the CARMA study with iTANK-armed CAR T-cell therapy

Elicera Therapeutics
Regulatory press release5/15/2025, 6:17 AM

Elicera Therapeutics AB (publ) Interim 1 January - 31 March 2025

Elicera Therapeutics
Press release4/14/2025, 7:39 AM

Elicera Therapeutics: BioStock: Green light to continue Elicera's CARMA-trial in B-cell lymphoma

Elicera Therapeutics
Press release4/10/2025, 12:44 PM

Elicera Therapeutics continues the Phase I/IIa CARMA study with its CAR T-cell therapy as planned following the safety committee's assessment of cohort 1

Elicera Therapeutics
Press release4/4/2025, 10:55 AM

Elicera Therapeutics' Chief Scientific Officer invited to speak at the Swedish Cancer Research Meeting 2025 on May 22

Elicera Therapeutics
Regulatory press release3/20/2025, 11:29 AM

Elicera Therapeutics resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO2

Elicera Therapeutics
Regulatory press release3/13/2025, 10:27 AM

Warrants of series TO2 in Elicera Therapeutics AB were subscribed to approximately 96.3 percent and the company resolves on a directed issue to underwriters

Elicera Therapeutics
Regulatory press release3/7/2025, 7:02 AM

The last day of trading with the warrants of series TO2 in Elicera Therapeutics is today, March 7, 2025

Elicera Therapeutics
Press release3/3/2025, 9:53 AM

Elicera Therapeutics: BioStock: Elicera's CEO: "TO2 is a highly attractive opportunity to increase ownership in Elicera"

Elicera Therapeutics
Press release2/28/2025, 10:46 AM

Correction: Board members and the executive management exercise warrants of series TO2 in Elicera Therapeutics

Elicera Therapeutics
Press release2/28/2025, 8:45 AM

Board members and the executive management exercise warrants of series TO2 in Elicera Therapeutics

Elicera Therapeutics
Regulatory press release2/25/2025, 12:01 PM

Elicera Therapeutics has secured 100 percent of the warrants of series TO2 corresponding to approximately SEK 22.0 million

Elicera Therapeutics
Regulatory press release2/25/2025, 7:29 AM

The exercise price for the warrants of series TO2 in Elicera Therapeutics has been determined to SEK 1.85

Elicera Therapeutics
Press release2/12/2025, 11:07 AM

BioStock: Elicera Therapeutics receives partial payment of 0,5 MEur from EIC

Elicera Therapeutics
Press release2/12/2025, 8:43 AM

Elicera Therapeutics Receives Notification of Partial Payment of EUR 500,000 from the European Innovation Council Accelerator Programme

Elicera Therapeutics
Press release2/10/2025, 12:30 PM

Elicera Therapeutics Presents Initial Clinical Data from the CARMA Study at ISCT 2025 in New Orleans

Elicera Therapeutics
Press release2/6/2025, 9:10 AM

Redeye: Elicera Therapeutics Q4 - Eventful 2025 ahead

Elicera Therapeutics
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team